{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:15:52Z","timestamp":1771665352564,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.gore.2026.102021","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:28:34Z","timestamp":1767832114000},"page":"102021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hypofractionated short course radiation therapy for recurrent ovarian cancer"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4367-1878","authenticated-orcid":false,"given":"Emily A.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amita","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff F.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Cantillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa K.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eloise","family":"Chapman-Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Higinia","family":"Cardenes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Holcomb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2026.102021_b0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","article-title":"Advances in ovarian cancer therapy","volume":"81","author":"Cortez","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.gore.2026.102021_b0010","doi-asserted-by":"crossref","unstructured":"Cardenes, H., & Randall, M. E. (2000, January). Integrating radiation therapy in the curative management of ovarian cancer: current issues and future directions. InSeminars in Radiation Oncology(Vol. 10, No. 1, pp. 61-70). WB Saunders.","DOI":"10.1016\/S1053-4296(00)80022-3"},{"issue":"5","key":"10.1016\/j.gore.2026.102021_b0015","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0360-3016(92)90777-F","article-title":"Epithelial ovarian cancer: the role of radiotherapy","volume":"22","author":"Dembo","year":"1992","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.gore.2026.102021_b0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fonc.2017.00177","article-title":"Radiation treatment in women with ovarian cancer: past, present, and future","volume":"7","author":"Fields","year":"2017","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2026.102021_b0025","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/0090-8258(90)90377-W","article-title":"Palliative benefit of radiation therapy in advanced ovarian cancer","volume":"37","author":"May","year":"1990","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2026.102021_b0030","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ygyno.2004.11.008","article-title":"Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer","volume":"96","author":"Albuquerque","year":"2005","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2026.102021_b0035","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ygyno.2013.04.469","article-title":"Involved-field radiation therapy for locoregionally recurrent ovarian cancer","volume":"130","author":"Brown","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2026.102021_b0040","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ygyno.2016.02.005","article-title":"Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy","volume":"141","author":"Chundury","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.gore.2026.102021_b0045","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol."},{"issue":"10237","key":"10.1016\/j.gore.2026.102021_b0050","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Brunt","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.gore.2026.102021_b0055","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.gore.2026.102021_b0060","article-title":"Benefits of adopting hypofractionated radiotherapy as a standard of care in low-and middle-income countries.JCO Global","volume":"8","author":"Kraus","year":"2022","journal-title":"Oncology"},{"key":"10.1016\/j.gore.2026.102021_b0065","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC)","volume":"31","author":"Jd","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.gore.2026.102021_b0070","first-page":"693","article-title":"Stereotactic ablative radiation therapy for oligometastatic ovarian cancer lymph node disease: the MITO-RT3\/RAD phase II trial. International Journal of Radiation Oncology* Biology*","volume":"121","author":"Macchia","year":"2025","journal-title":"Physics"},{"issue":"20","key":"10.1016\/j.gore.2026.102021_b0075","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.gore.2026.102021_b0080","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol."},{"issue":"23","key":"10.1016\/j.gore.2026.102021_b0085","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.gore.2026.102021_b0090","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","article-title":"A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study): a collaboration of MITO, AIRO GYN, and MaNGO groups","volume":"25","author":"Macchia","year":"2020","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.gore.2026.102021_b0095","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","article-title":"Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday","volume":"101","author":"Lazzari","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926000019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926000019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:22:06Z","timestamp":1771662126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926000019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":19,"alternative-id":["S2352578926000019"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102021","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypofractionated short course radiation therapy for recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102021"}}